Author Topic: (Abst.) Bryostatin-1 alleviates experimental MS  (Read 109 times)

0 Members and 1 Guest are viewing this topic.

Offline agate

  • Administrator
  • *****
  • Posts: 9822
  • MS diagnosed 1980
  • Location: Pacific Northwest
(Abst.) Bryostatin-1 alleviates experimental MS
« on: February 15, 2018, 09:34:57 am »
Abstract of "Bryostatin-1 alleviates experimental multiple sclerosis" by several Johns Hopkins researchers and published in PNAS (Proceedings of the National Academy of Sciences). From PubMed, February 15, 2018:


https://www.ncbi.nlm.nih.gov/pubmed/29440425


From the abstract:


Quote
More strikingly, bryo-1 reverses neurologic deficits after EAE onset, even when treatment is initiated at a late stage of disease when peak adaptive immunity has subsided.
And:

Quote
These findings suggest the potential for bryo-1 as a therapeutic agent in MS, particularly given its established clinical safety. Furthermore, the benefit of bryo-1, even in late treatment of EAE, combined with its targeting of innate myeloid cells suggests therapeutic potential in progressive forms of MS.

MS Speaks--online for 17 years

SPMS, diagnosed 1980. Avonex 2001-2004. Copaxone 2007-2010. Glatopa (glatiramer acetate 40mg 3 times/week) since 12/16/20.

 

Related Topics

  Subject / Started by Replies Last post
0 Replies
110 Views
Last post May 01, 2016, 04:22:34 pm
by agate
0 Replies
197 Views
Last post October 13, 2016, 05:53:43 am
by agate
0 Replies
117 Views
Last post May 07, 2017, 02:14:43 pm
by agate
0 Replies
104 Views
Last post May 14, 2017, 02:52:21 pm
by agate
0 Replies
455 Views
Last post May 16, 2017, 11:53:39 am
by agate